Drug intelligence / Profile preview

ALKALA T

Development stage: Unknown
Lead developer: Sanum-Kehlbeck
Modality: Small Molecules
Administration: Oral

Overview

ALKALA T is an over-the-counter antacid product developed by Sanum-Kehlbeck GmbH & Co. KG. It is formulated as an oral tablet containing sodium hydrogen carbonate (sodium bicarbonate) as the primary active ingredient. The product is traditionally used for the symptomatic relief of heartburn and acid-related stomach disorders, including gastroesophageal reflux disease (GERD), sour stomach, and dyspepsia. ALKALA T functions through the direct chemical neutralization of gastric acid at the site of action in the stomach. It is part of the Sanum therapy system's base regulation product line, intended to help regulate acid-base balance in the body.

Brand names: ALKALA T
Other names: ALKALA T tabletsAlkala T Sanum

Beyond the preview

Go deeper on ALKALA T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ALKALA T.

Explore the full profile